Vaccinex publishes melanoma findings: what they mean for Vaccinex stock

Published on 10/16/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaccinex reported findings from a 38-patient melanoma study on October 7, 2026. For Vaccinex stock, the study was not powered to prove efficacy.

Melanoma study evidence

Vaccinex reported results from a 38-patient melanoma study on October 7, 2026.
The trial used two pepinemab doses before surgery.
No grade 4 or 5 adverse events occurred during treatment.

VCNX, US9186403013, Illustration mit AI erstellt.

Vaccinex (ISIN US9186403013) reported findings from a 38-patient melanoma study on October 7, 2026, after researchers evaluated pepinemab with checkpoint inhibitors before surgery. GlobeNewswire carried the company announcement. The study met its predefined primary biomarker endpoint, but it was not designed or powered to establish clinical efficacy.

What did the melanoma study show?

The treatment combined pepinemab with nivolumab and/or ipilimumab and was administered before curative-intent surgery. Vaccinex said the regimens were associated with changes in the tumor microenvironment, including immune-cell recruitment, antigen presentation and mature lymphoid aggregates.

The small study produced a mixed evidence profile. Greater abundance of mature lymphoid aggregates was associated with longer recurrence-free survival, while the company said larger randomized studies would be needed to confirm a clinical benefit. No grade 4 or 5 adverse events occurred during treatment before or after surgery.

Three dated steps for Vaccinex

ToAlpha lists a DEF 14A filing dated September 10, 2026, an S-1 filing dated September 17, 2026, and the October 7, 2026 melanoma publication as recent company events.

The investment case remains tied to clinical development rather than product revenue. On its investor overview, Vaccinex describes pepinemab as its lead candidate for neurodegenerative disease and cancer and identifies SEMA4D inhibition as the central research approach.

Clinical evidence remains the market test

The October 7 publication strengthens the biological rationale around pepinemab, but its own limitations set the appropriate reading: biomarker changes and an association with recurrence-free survival are not equivalent to proof of efficacy. On OTC Markets, Vaccinex last closed at USD 1.00 on October 14, 2026.